Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 9, 2008

ImmunoCellular Licenses CSC-Targeted Peptides from Cedars-Sinai for Use in Treating Gliomas

  • ImmunoCellular Therapeutics has exclusively licensed from Cedars-Sinai Medical Center peptides tjhat the company believes can stimulate the immune system to target cancer stem cells (CSCs) in gliomas. These peptides were specifically designed to elicit a T-cell response targeting CD133-positive CSCs.